{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T18:25:27Z","timestamp":1759775127782},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.ygyno.2009.05.036","type":"journal-article","created":{"date-parts":[[2009,6,27]],"date-time":"2009-06-27T04:36:28Z","timestamp":1246077388000},"page":"420-423","source":"Crossref","is-referenced-by-count":11,"title":["Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: A single institution's experience"],"prefix":"10.1016","volume":"114","author":[{"given":"Joseph J.","family":"Ivy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Geller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena M.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Jonson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Argenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ygyno.2009.05.036_bib1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"17","key":"10.1016\/j.ygyno.2009.05.036_bib2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2009.05.036_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00280-003-0680-2","article-title":"Pharmokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions","volume":"52","author":"Mohamed","year":"2003","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib4","first-page":"1","article-title":"Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer","volume":"62","author":"Dedrick","year":"1978","journal-title":"Cancer Treat. Rep."},{"issue":"4","key":"10.1016\/j.ygyno.2009.05.036_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0305-7372(86)90007-1","article-title":"Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity","volume":"13","author":"Markman","year":"1986","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.ygyno.2009.05.036_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00000441-198603000-00006","article-title":"Cytotoxic intracavitary chemotherapy","volume":"291","author":"Markman","year":"1986","journal-title":"Am. J. Med. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2009.05.036_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1525-1438.2007.01099.x","article-title":"Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer","volume":"18","author":"Howell","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2009.05.036_bib8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.7326\/0003-4819-97-6-845","article-title":"Intraperitoneal cisplatin with systemic thiosulfate protection","volume":"97","author":"Howell","year":"1982","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ygyno.2005.11.013","article-title":"Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"100","author":"Walker","year":"2006","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.05.036_bib11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ygyno.2007.10.004","article-title":"Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates","volume":"108","author":"Landrum","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygyno.2007.12.004","article-title":"Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer","volume":"109","author":"Black","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.05.036_bib13","unstructured":"Intraperitoneal chemotherapy for ovarian cancer NCI announcement, available January 2006 at ctep.Cancergov\/highlights\/docs\/clin_annc_010506.pdf."},{"issue":"3","key":"10.1016\/j.ygyno.2009.05.036_bib14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1006\/gyno.1994.1220","article-title":"A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer","volume":"54","author":"Kirmani","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2009.05.036_bib15","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ygyno.2009.05.036_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000011980","article-title":"A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer","volume":"56","author":"Polyzos","year":"1999","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.ygyno.2009.05.036_bib17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","article-title":"Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group","volume":"19","author":"Markman","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0020-7292(00)00340-4","article-title":"Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer","volume":"72","author":"Yen","year":"2001","journal-title":"Int. J. Gynaecol. Obstet."},{"issue":"2","key":"10.1016\/j.ygyno.2009.05.036_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/gyno.1999.5677","article-title":"Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest","volume":"76","author":"Gadducci","year":"2000","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2009.05.036_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2000.6108","article-title":"Complications associated with intraperitoneal chemotherapy catheters","volume":"81","author":"Makhija","year":"2001","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2009.05.036_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0090-8258(91)90266-8","article-title":"Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system","volume":"41","author":"Davidson","year":"1991","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.05.036_bib22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0090-8258(86)90083-1","article-title":"Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis","volume":"25","author":"Braly","year":"1986","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2009.05.036_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1006\/gyno.2000.5979","article-title":"Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma","volume":"79","author":"Sakuragi","year":"2000","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809004120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809004120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T23:39:24Z","timestamp":1558395564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809004120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0090825809004120"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.05.036","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}